Stage IIIC Cutaneous Melanoma AJCC v7 Active Not Recruiting Phase 3 Trials for Pembrolizumab (DB09037)

IndicationStatusPhase
DBCOND0091049 (Stage IIIC Cutaneous Melanoma AJCC v7)Active Not Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02506153High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryTreatment